Gland Pharma Limited (BOM:543245)

Gland Pharma Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Operating Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Net Income	10,273	6,985	7,725	7,810	12,117
Depreciation & Amortization	4,237	3,779	3,446	1,467	1,103
Loss (Gain) From Sale of Assets	3.84	0.32	-2.49	0.81	1.78
Asset Writedown & Restructuring Costs	-	18.24	-	63.32	-
Loss (Gain) From Sale of Investments	-33.06	-12.27	-3.48	-28.48	-44.89
Stock-Based Compensation	454.68	-	-	-	46.21
Provision & Write-off of Bad Debts	5.45	46.23	214.21	22.04	41.27
Other Operating Activities	-2,082	-1,609	-878.54	-1,516	-1,426
Change in Accounts Receivable	-2,786	422.88	-3,250	1,440	-4,196
Change in Inventory	187.23	-199.18	6,661	-7,596	895.01
Change in Accounts Payable	-548.83	269.03	-3,789	1,210	659.19
Change in Other Net Operating Assets	602.83	-553.36	-154.51	767.19	-1,289
Operating Cash Flow	10,314	9,147	9,968	3,640	7,908
Operating Cash Flow Growth	12.75%	-8.23%	173.87%	-53.97%	30.72%

Investing Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Capital Expenditures	-4,908	-3,845	-3,899	-2,209	-5,113
Sale of Property, Plant & Equipment	5.89	3.38	7.67	1.4	3.99
Cash Acquisitions	-	-	-10,218	-	-
Sale (Purchase) of Intangibles	-36.66	-96.24	-83.26	-21.9	-107.92
Investment in Securities	3,993	19,421	-4,747	12,706	-6,117
Other Investing Activities	2,323	1,565	1,371	1,606	1,308
Investing Cash Flow	1,377	17,047	-17,569	12,082	-10,026

Financing Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Long-Term Debt Issued	225.23	52.83	210.28	-	-
Long-Term Debt Repaid	-1,106	-811.64	-7,954	-2.9	-2.52
Total Debt Repaid	-1,106	-811.64	-7,954	-2.9	-2.52
Net Debt Issued (Repaid)	-880.62	-758.81	-7,743	-2.9	-2.52
Issuance of Common Stock	-	24.88	5.26	214.96	385.52
Common Dividends Paid	-2,966	-3,295	-	-	-
Other Financing Activities	-323.58	-305.95	-256.11	-62.87	-34.02
Financing Cash Flow	-4,170	-4,335	-7,994	149.19	348.98

Net Cash Flow

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Foreign Exchange Rate Adjustments	507.53	131.31	77.23	30	33.11
Net Cash Flow	8,029	21,991	-15,518	15,901	-1,736

Free Cash Flow

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Free Cash Flow	5,406	5,302	6,069	1,430	2,794
Free Cash Flow Growth	1.97%	-12.63%	324.27%	-48.81%	-25.71%
Free Cash Flow Margin	8.41%	9.44%	10.71%	3.95%	6.35%
Free Cash Flow Per Share	32.77	32.18	36.84	8.69	16.98
Levered Free Cash Flow	5,041	5,719	4,104	875.11	493.54
Unlevered Free Cash Flow	5,249	5,953	4,240	914.4	514.8

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash Interest Paid	323.58	305.95	256.11	62.87	34.02
Cash Income Tax Paid	4,555	3,538	3,061	3,109	4,065
Change in Working Capital	-2,545	-60.63	-531.99	-4,179	-3,930

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 28, 2026

Data Sources Report a data error